Trial Profile
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics
- Sponsors TesoRx
- 13 Aug 2018 Status changed from active, no longer recruiting to discontinued due to Incomplete effect
- 21 May 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2017 According to a TesoRx Pharma media release, enrollment will include at least 10 evaluable native Japanese subjects intended to contribute towards TSX-011 regulatory approval efforts in Japan. Top-line results from this trial are expected in the second half of 2018.